KR20060002501A - 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 - Google Patents
다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 Download PDFInfo
- Publication number
- KR20060002501A KR20060002501A KR1020040051558A KR20040051558A KR20060002501A KR 20060002501 A KR20060002501 A KR 20060002501A KR 1020040051558 A KR1020040051558 A KR 1020040051558A KR 20040051558 A KR20040051558 A KR 20040051558A KR 20060002501 A KR20060002501 A KR 20060002501A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- group
- preparing
- trityloxymethyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- HHZZOQSDZBZQFK-UHFFFAOYSA-N [1-[di(propan-2-yloxy)phosphorylmethoxy]cyclopropyl]methanol Chemical compound CC(C)OP(=O)(OC(C)C)COC1(CO)CC1 HHZZOQSDZBZQFK-UHFFFAOYSA-N 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 28
- -1 ethyl magnesium halide Chemical class 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- QJTROUHNWPQATP-UHFFFAOYSA-N 1-(trityloxymethyl)cyclopropan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OCC1(O)CC1 QJTROUHNWPQATP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 claims description 8
- KOMSQTMQKWSQDW-UHFFFAOYSA-N ethyl 5-methyl-1,2-oxazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NOC=1C KOMSQTMQKWSQDW-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000460 chlorine Chemical group 0.000 claims description 4
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 2
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical group [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 claims description 2
- DQGUAEKECXYVHT-UHFFFAOYSA-N C(C1=CC=CC=C1)(C1=CC=CC=C1)(C1=CC=CC=C1)OCC1(CC1)OCP(O)(O)=O Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)(C1=CC=CC=C1)OCC1(CC1)OCP(O)(O)=O DQGUAEKECXYVHT-UHFFFAOYSA-N 0.000 claims 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 11
- 230000002194 synthesizing effect Effects 0.000 abstract description 8
- 239000003443 antiviral agent Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 239000002777 nucleoside Substances 0.000 abstract description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 241000700721 Hepatitis B virus Species 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 18
- KLPTYUXPTXPKDQ-UHFFFAOYSA-N [[1-[di(propan-2-yloxy)phosphorylmethoxy]cyclopropyl]methoxy-diphenylmethyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OCC1(OCP(=O)(OC(C)C)OC(C)C)CC1 KLPTYUXPTXPKDQ-UHFFFAOYSA-N 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 5
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 2
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 229910052740 iodine Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- 0 *c1c2nc[n](CC3(CC3)OCP(O)(O)=O)c2nc(*2C3C2C3)n1 Chemical compound *c1c2nc[n](CC3(CC3)OCP(O)(O)=O)c2nc(*2C3C2C3)n1 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- BJLZAAWLLPMZQR-UHFFFAOYSA-N oxo-di(propan-2-yloxy)phosphanium Chemical compound CC(C)O[P+](=O)OC(C)C BJLZAAWLLPMZQR-UHFFFAOYSA-N 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (7)
- 하기 화학식 4의 화합물을 트리틸 클로라이드와 반응시켜 하기 화학식 8의 트리틸옥시-아세트산 에틸 에스터를 제조하고, 이를 에틸 마그네슘 할라이드와 반응시켜 하기 화학식 9의 1-트리틸옥시메틸-사이클로프로판올을 제조하며, 화학식 9의 1-트리틸옥시메틸-사이클로프로판올을 용매중에서 다이아이소프로필브로모메틸 포스포네이트와 결합시켜 하기 화학식 10의 (1-트리틸옥시메틸-사이클로프로폭시메틸)-포스폰산 다이아이소프로필 에스터를 제조하고 이를 고체로 얻은 다음, 화학식 10 화합물의 트리틸기를 하이드록실기로 전환시킴을 특징으로 하여 하기 화학식 2의 화합물을 제조하는 방법:[화학식 4][화학식 8][화학식 9][화학식 10][화학식 2]
- 제1항에 있어서, 화학식 9의 화합물을 반응시켜 화학식 10의 화합물을 제조하는 단계에서 사용되는 용매가 N-메틸피롤리돈인 방법.
- 제1항에 있어서, 에틸 마그네슘 할라이드가 에틸 마그네슘 클로라이드 또는 에틸 마그네슘 브로마이드인 방법.
- 제1항에 있어서, 화학식 10 화합물의 트리틸기를 하이드록실기로 전환시킨 후, 수산화나트륨으로 처리하여 생성된 고체를 여과하고 여액을 메틸렌클로라이드로 추출하여 화학식 2의 화합물을 얻는 방법.
- 제1항의 방법에 따라 제조한 화학식 2의 화합물에 이탈기를 도입시켜 하기 화학식 11의 화합물을 수득하고, 화학식 11의 화합물을 화학식 3의 화합물과 커플링 반응시켜 하기 화학식 12의 화합물을 수득하며, 화학식 12의 화합물을 가수분해하여 하기 화학식 13의 화합물을 수득하고, 화학식 13의 화합물로부터 그룹 X를 제거함과 동시에 포스폰산 부위에 t-부틸카보닐옥시메틸 그룹을 도입시킴을 특징으로 하여 하기 화학식 1의 화합물을 제조하는 방법:[화학식 11][화학식 3][화학식 12][화학식 13][화학식 1]상기 식에서X는 불소, 염소, 브롬, 또는 요오드를 나타내고,L은 이탈기를 나타낸다.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040051558A KR101033290B1 (ko) | 2004-07-02 | 2004-07-02 | 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 |
EP05765985A EP1765838A4 (en) | 2004-07-02 | 2005-06-27 | PREPARATION FOR DI-ISOPROPYL ((1 (HYDROXYMETHYL) -CYCLOPROPYL) OXY) METHYL PHOSPHONATE |
MXPA06015262A MXPA06015262A (es) | 2004-07-02 | 2005-06-27 | Proceso para preparar ((1(hidroximetil)-ciclopropil)oxi) metilfosfonato de di-isopropilo. |
US11/631,263 US7795463B2 (en) | 2004-07-02 | 2005-06-27 | Process for preparing diisopropyl((1-(hydroxymethyl)-cyclopropyl)oxy)methylphosphonate |
JP2007519120A JP4422183B2 (ja) | 2004-07-02 | 2005-06-27 | ジイソプロピル((1−(ヒドロキシメチル)−シクロプロピル)オキシ)メチルホスホネートの製造方法 |
TW094121379A TWI326685B (en) | 2004-07-02 | 2005-06-27 | Process for preparing diisopropyl((1-(hydroxymethyl)-cyclopropyl)oxy)methylphosphonate |
BRPI0512886-2A BRPI0512886A (pt) | 2004-07-02 | 2005-06-27 | processo para preparar um composto, e, composto |
AU2005260375A AU2005260375B8 (en) | 2004-07-02 | 2005-06-27 | Process for preparing di-isopropyl ((1(hydroxymethyl)-cyclopropyl)oxy) methylphosphonate |
PCT/KR2005/002007 WO2006004330A1 (en) | 2004-07-02 | 2005-06-27 | Process for preparing di-isopropyl ((1(hydroxymethyl)-cyclopropyl)oxy) methylphosphonate |
NZ552246A NZ552246A (en) | 2004-07-02 | 2005-06-27 | Process for preparing di-isopropyl ((1(hydroxymethyl)-cyclopropyl)oxy) methylphosphonate |
CA2571592A CA2571592C (en) | 2004-07-02 | 2005-06-27 | Process for preparing diisopropyl((1-(hydroxymethyl)-cyclopropyl)oxy) methylphosphonate |
RU2007104036/04A RU2326885C1 (ru) | 2004-07-02 | 2005-06-27 | Способ получения диизопропил ((1-(гидроксиметил)-циклопропил)окси) метилфосфоната |
CN2005800221766A CN101061128B (zh) | 2004-07-02 | 2005-06-27 | 制备二异丙基((1-(羟甲基)-环丙基)氧)甲基膦酸酯的方法 |
ARP050102748A AR049566A1 (es) | 2004-07-02 | 2005-07-01 | Procedimiento para preparar diisopropil((1-(hidroximetil)-ciclopropil)oxi)metilfosfonato |
ZA200610744A ZA200610744B (en) | 2004-07-02 | 2006-12-20 | Process for preparing di-isopropyl ((1(hydroxymethyl)-cyclopropyl)oxy) methylphosphonate |
US12/853,440 US20100305364A1 (en) | 2004-07-02 | 2010-08-10 | Process for preparing diisopropyl((1-(hydroxymethyl)-cyclopropyl)oxy)methylphosphonate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040051558A KR101033290B1 (ko) | 2004-07-02 | 2004-07-02 | 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060002501A true KR20060002501A (ko) | 2006-01-09 |
KR101033290B1 KR101033290B1 (ko) | 2011-05-09 |
Family
ID=36940541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040051558A KR101033290B1 (ko) | 2004-07-02 | 2004-07-02 | 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 |
Country Status (15)
Country | Link |
---|---|
US (2) | US7795463B2 (ko) |
EP (1) | EP1765838A4 (ko) |
JP (1) | JP4422183B2 (ko) |
KR (1) | KR101033290B1 (ko) |
CN (1) | CN101061128B (ko) |
AR (1) | AR049566A1 (ko) |
AU (1) | AU2005260375B8 (ko) |
BR (1) | BRPI0512886A (ko) |
CA (1) | CA2571592C (ko) |
MX (1) | MXPA06015262A (ko) |
NZ (1) | NZ552246A (ko) |
RU (1) | RU2326885C1 (ko) |
TW (1) | TWI326685B (ko) |
WO (1) | WO2006004330A1 (ko) |
ZA (1) | ZA200610744B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10910338B2 (en) | 2016-08-01 | 2021-02-02 | Samsung Display Co., Ltd. | Electronic device having an under-fill element, a mounting method of the same, and a method of manufacturing a display apparatus having the electronic device |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI384986B (zh) * | 2007-01-17 | 2013-02-11 | Lg Life Sciences Ltd | 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物 |
CN106432330B (zh) * | 2015-08-11 | 2019-02-01 | 天津科伦药物研究有限公司 | Lb80380药物的中间体化合物及其制备方法和用途 |
CN108997429B (zh) * | 2018-07-27 | 2020-10-30 | 广州粤美医药科技有限公司 | 一种制备贝西福韦的方法 |
CN115181013B (zh) * | 2022-07-22 | 2023-08-08 | 北京先通国际医药科技股份有限公司 | 修饰脂肪酸型pet试剂前体关键中间体的制备方法及其用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
WO1993007157A1 (en) | 1991-10-11 | 1993-04-15 | Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic | Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives |
US5817647A (en) * | 1993-04-01 | 1998-10-06 | Merrell Pharmaceuticals Inc. | Unsaturated acetylene phosphonate derivatives of purines |
MY141789A (en) * | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
GB0117950D0 (en) * | 2001-02-16 | 2001-09-19 | Aventis Pharma Inc | Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands |
CN1684970A (zh) * | 2002-09-26 | 2005-10-19 | 株式会社Lg生命科学 | (1-膦酰甲氧基-2-烷基环丙基) 甲基核苷衍生物的(+)-反式-异构体、用于制备其立体异构体的方法、及其抗病毒剂的用途 |
EP1715873A1 (en) * | 2004-02-17 | 2006-11-02 | LG Life Sciences Ltd. | Nucleoside phosphonate derivatives useful in the treatment of hiv infections |
-
2004
- 2004-07-02 KR KR1020040051558A patent/KR101033290B1/ko active Protection Beyond IP Right Term
-
2005
- 2005-06-27 US US11/631,263 patent/US7795463B2/en not_active Expired - Fee Related
- 2005-06-27 CA CA2571592A patent/CA2571592C/en not_active Expired - Fee Related
- 2005-06-27 MX MXPA06015262A patent/MXPA06015262A/es active IP Right Grant
- 2005-06-27 BR BRPI0512886-2A patent/BRPI0512886A/pt not_active IP Right Cessation
- 2005-06-27 TW TW094121379A patent/TWI326685B/zh not_active IP Right Cessation
- 2005-06-27 CN CN2005800221766A patent/CN101061128B/zh active Active
- 2005-06-27 AU AU2005260375A patent/AU2005260375B8/en not_active Ceased
- 2005-06-27 WO PCT/KR2005/002007 patent/WO2006004330A1/en active Application Filing
- 2005-06-27 JP JP2007519120A patent/JP4422183B2/ja active Active
- 2005-06-27 NZ NZ552246A patent/NZ552246A/en not_active IP Right Cessation
- 2005-06-27 RU RU2007104036/04A patent/RU2326885C1/ru not_active IP Right Cessation
- 2005-06-27 EP EP05765985A patent/EP1765838A4/en not_active Withdrawn
- 2005-07-01 AR ARP050102748A patent/AR049566A1/es active IP Right Grant
-
2006
- 2006-12-20 ZA ZA200610744A patent/ZA200610744B/en unknown
-
2010
- 2010-08-10 US US12/853,440 patent/US20100305364A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10910338B2 (en) | 2016-08-01 | 2021-02-02 | Samsung Display Co., Ltd. | Electronic device having an under-fill element, a mounting method of the same, and a method of manufacturing a display apparatus having the electronic device |
Also Published As
Publication number | Publication date |
---|---|
US20100305364A1 (en) | 2010-12-02 |
MXPA06015262A (es) | 2007-03-21 |
CA2571592C (en) | 2010-02-09 |
US7795463B2 (en) | 2010-09-14 |
RU2326885C1 (ru) | 2008-06-20 |
EP1765838A4 (en) | 2009-05-27 |
ZA200610744B (en) | 2008-05-28 |
KR101033290B1 (ko) | 2011-05-09 |
AU2005260375B2 (en) | 2010-12-09 |
JP2008505066A (ja) | 2008-02-21 |
CN101061128B (zh) | 2010-10-06 |
EP1765838A1 (en) | 2007-03-28 |
BRPI0512886A (pt) | 2008-04-15 |
WO2006004330A1 (en) | 2006-01-12 |
NZ552246A (en) | 2009-07-31 |
AR049566A1 (es) | 2006-08-16 |
TWI326685B (en) | 2010-07-01 |
AU2005260375B8 (en) | 2011-01-20 |
JP4422183B2 (ja) | 2010-02-24 |
RU2007104036A (ru) | 2008-08-10 |
AU2005260375A1 (en) | 2006-01-12 |
US20090187019A1 (en) | 2009-07-23 |
TW200606170A (en) | 2006-02-16 |
CA2571592A1 (en) | 2006-01-12 |
CN101061128A (zh) | 2007-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5266194B2 (ja) | プロテアーゼインヒビターとして有用な4−ヒドロキシ−2−オキソ−ピラン誘導体の製法 | |
JP6421172B2 (ja) | マシテンタンの製造に有用なピリミジン中間体の製造 | |
CN107011260A (zh) | 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体 | |
TW200831469A (en) | Chemical process | |
US20100305364A1 (en) | Process for preparing diisopropyl((1-(hydroxymethyl)-cyclopropyl)oxy)methylphosphonate | |
WO2012041015A1 (zh) | 一种非环核苷类抗病毒药物磷酸单酯化合物的制备方法 | |
KR101832238B1 (ko) | 신규한 설포닐옥시메틸포스포네이트 유도체 및 이를 이용한 다이아이소프로필 ((1-(트리틸옥시메틸)-사이클로프로필)옥시)메틸 포스포네이트의 제조방법 | |
KR101134021B1 (ko) | 새로운 중간체를 이용하는 피타바스타틴 헤미칼슘의 신규한 제조방법 | |
KR101195631B1 (ko) | 9-[2-(포스포노메톡시)에틸]아데닌의 개선된 제조방법 | |
KR101088488B1 (ko) | 광학활성을 갖는 암로디핀의 제조방법 | |
CA2137049A1 (en) | Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds | |
KR102379965B1 (ko) | 테노포비르의 효율적인 제조방법 | |
JPWO2006038719A1 (ja) | ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤 | |
US8999958B2 (en) | Forms of cidofovir | |
CN114195748A (zh) | 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法 | |
JPH0649669B2 (ja) | 光学活性アルコールの製法 | |
JP2006076897A (ja) | 4−アルキル−5−ホルミルチアゾール環状アセタール誘導体、その製造方法及び4−アルキル−5−ホルミルチアゾールの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140311 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150316 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160304 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170306 Year of fee payment: 7 |
|
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20180418 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190401 Year of fee payment: 9 |